Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F12%3A%230000247" target="_blank" >RIV/00209775:_____/12:#0000247 - isvavai.cz</a>

Výsledek na webu

<a href="http://plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048851" target="_blank" >http://plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048851</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1371/journal.pone.0048851" target="_blank" >10.1371/journal.pone.0048851</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated

Popis výsledku v původním jazyce

The aim of the work was to find biomarkers identifying patients at high risk of adverse clinical outcomes after TAVI and SAVR in addition to currently used predictive model (EuroSCORE). There is limited data about the role of biomarkers in predicting prognosis, especially when TAVI is available. The multi-biomarker sub-study included 42 consecutive high-risk patients allocated to TAVI tranfemoral and transapical (n=29), or SAVR (n=13). Standardized endpoints were prospectively followed during the 12-month follow-up. The clinical outcomes after both TAVI and SAVR were comparable. Malondialdehyde served as the best predictor of a combined endpoint at 1 year with AUC (ROC analysis) = 0.872 for TAVI group, resp. 0.765 (p<0.05) for both TAVI and SAVR groups. Increased levels of MDA, matrix metalloproteinase 2, tissue inhibitor of metalloproteinase (TIMP1), ferritin-reducing ability of plasma, homocysteine, cysteine and 8-hydroxy-2-deoxyguanosine were all predictors of the occurrence of comb

Název v anglickém jazyce

Prognostic utility of biomarkers in predicting of one-year outcomes in patients with aortic stenosis treated

Popis výsledku anglicky

The aim of the work was to find biomarkers identifying patients at high risk of adverse clinical outcomes after TAVI and SAVR in addition to currently used predictive model (EuroSCORE). There is limited data about the role of biomarkers in predicting prognosis, especially when TAVI is available. The multi-biomarker sub-study included 42 consecutive high-risk patients allocated to TAVI tranfemoral and transapical (n=29), or SAVR (n=13). Standardized endpoints were prospectively followed during the 12-month follow-up. The clinical outcomes after both TAVI and SAVR were comparable. Malondialdehyde served as the best predictor of a combined endpoint at 1 year with AUC (ROC analysis) = 0.872 for TAVI group, resp. 0.765 (p<0.05) for both TAVI and SAVR groups. Increased levels of MDA, matrix metalloproteinase 2, tissue inhibitor of metalloproteinase (TIMP1), ferritin-reducing ability of plasma, homocysteine, cysteine and 8-hydroxy-2-deoxyguanosine were all predictors of the occurrence of comb

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Plos One

ISSN

1932-6203

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

—

Kód UT WoS článku

000312386800004

EID výsledku v databázi Scopus

—